# Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

> **NCT05769777** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 999 (actual)

## Conditions studied

- Dermatitis Atopic

## Interventions

- **DRUG:** Amlitelimab

## Key facts

- **NCT ID:** NCT05769777
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-03
- **Primary completion:** 2031-06-11
- **Final completion:** 2031-06-11
- **Target enrollment:** 999 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769777, "Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05769777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*